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357Abstracts
The economic burden of the disease in this study was
deﬁned as the sum of direct costs and indirect costs.
Direct costs include physician, non-physician, outpatient,
inpatient, emergency room, and home healthcare ex-
penses. Indirect costs include working days missed 
and wages lost due to illness. RESULTS: The direct 
cost for 703 patients diagnosed with depression was
US$4,973,140 and the indirect cost was US$183,855.
The economic burden was US$5,156,995 and the aver-
age cost was US$7,336/patient/year. The average co-
morbidity for the sample of 703 patients was 4.8, with a
minimum of one and maximum of 19. CONCLUSIONS:
The average cost of depression of US$7336/patient/year
is three-fold higher (after adjusting for inﬂation) than the
1990 estimate of US$1600/patient/year as obtained from
the National Institute of Mental Health report. Thus,
there is signiﬁcant economic burden of depression on the
US healthcare system. Regulating prescription costs along
with increased patient awareness may help in reducing the
economic burden of depression.
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OBJECTIVES: This study compared the costs in claims
associated with ﬁbromyalgia plus depression, ﬁbromyal-
gia alone, and depression alone. METHODS: Using
administrative claims data from a national Fortune 100
manufacturer, 3 mutually exclusive cohorts and an overall
beneﬁciary cohort were deﬁned based on diagnostic
claims: ﬁbromyalgia-only, depression-only, ﬁbromyalgia
plus depression, and a random sample comprising 10%
of the employer’s overall beneﬁciary sample. The cohorts
were compared for demographics, comorbid conditions,
health care resources used, medication use by therapeu-
tic class, and mean direct costs and imputed indirect 
costs. RESULTS: Mean annual costs per patient to the
employer were $5,163 for ﬁbromyalgia-only, $8,073 for
depression-only, $11,899 for ﬁbromyalgia plus depres-
sion, and $2,486 for patients in the overall sample. Mean
incremental employer costs (above overall sample pay-
ments) per patient for those with ﬁbromyalgia plus
depression were a cost addition of $1,149 when com-
pared with the sum of the incremental costs for those with
ﬁbromyalgia-only and depression-only ((11,899 - 2,486)
- (5,163 - 2,486) + (8,073 - 2,486)). For every dollar
spent on ﬁbromyalgia healthcare costs for employees
(medical care plus prescriptions), the employer spent $57
to $143 on additional direct and indirect costs. CON-
CLUSIONS: Patients with both ﬁbromyalgia and depres-
sion claims are high users of the health care system.
Although data are limited to an insured population, they
concur with previous literature establishing relationships
between depression and painful conditions. When
ﬁbromyalgia and depression co-occur there is more than
additive relationship between the incremental costs versus
single syndrome cohorts. Improved management of these
patients could result in reduced patient, physician and
employer burdens.
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OBJECTIVES: Although much information has been
published on St. John’s Wort, the question of cost-
effectiveness remains to be addressed. The objective of
this study was to determine the cost-effectiveness of St.
John’s Wort compared to ﬂuoxetine from a third party
perspective for the treatment of mild to moderate depres-
sion. METHODS: An expert panel of two psychiatrists,
one pharmacist, and three primary care physicians was
surveyed to establish a decision analytic model of depres-
sion management in the outpatient setting over a treat-
ment period of one year. Treatment with ﬂuoxetine 20mg
daily was compared to treatment with St. John’s Wort
300mg thrice daily for patients diagnosed with mild to
moderate depression. Probabilities of the various out-
comes included in the decision tree were obtained from a
Medline search as well as the survey of the expert panel.
Direct medical costs of physician and psychologist visits
and lab tests were obtained from medical ofﬁces in the
Connecticut area. Cost of ﬂuoxetine and the herb were
based on 2002 published data. The cost per successfully
treated patient was evaluated for both therapies. One-
way and multi-way sensitivity analyses were performed
to determine the robustness of the data. RESULTS: The
base case analysis yielded a cost-effectiveness ratio of
$1788 per successful treatment with St. John’s Wort com-
pared to $2043 per successful treatment with ﬂuoxetine.
The results remained relatively robust to ﬂuctuations in
values of all variables. However, cost of therapy proved
to be an important determinant in overall cost-
effectiveness. At a cost of $20.00 per month, ﬂuoxetine
becomes the more cost-effective agent when St. John’s
Wort remains above $16.00 per month. CONCLU-
SIONS: St. John’s Wort is a viable option for patients with
mild to moderate depression in terms of both efﬁcacy and
cost. Consideration should be given for addition to third
party payers’ formularies.
